NASDAQ: RNAAtrium Therapeutics Inc Stock
$13.43+0.66 (+5.17%)
Updated May 1, 2026
RNA Price
$13.43
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$11.95
52 Week High
$16.77
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$18.62M
Earnings
-$49.50M
Gross Margin
100%
Operating Margin
-266.64%
Profit Margin
-265.9%
Debt to Equity
-1.13
Operating Cash Flow
-$41M
Beta
0.77
Next Earnings
May 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
RNA Overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RNA news, forecast changes, insider trades & much more!
RNA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNA's cash and short-term investments ($0.00) cannot cover RNA's cash burn for the next year (N/A), even if decreasing cash burn (N/A) is accounted for
Interest Coverage Financials
RNA's profit margin has decreased (-35.4%) in the last year from (-230.5%) to (-265.9%)
Profit Margin Growth Financials
RNA's short-term liabilities ($41.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more RNA due diligence checks available for Premium users.
Valuation
RNA fair value
Fair Value of RNA stock based on Discounted Cash Flow (DCF)
Price
$13.43
Fair Value
-$5.78
Undervalued by
332.55%
RNA's financial health
Profit margin
Revenue
$859.0k
Net Income
-$29.1M
Profit Margin
-3,391.9%
RNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.4M
Liabilities
$71.1M
Debt to equity
-1.13
RNA's short-term liabilities ($41.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNA's long-term liabilities ($29.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.3M
Investing
-$879.0k
Financing
$20.1M
RNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Atrium Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.